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INTRODUCTION
•

•

DIAGNOSTICS

TEST
Valproic Acid Level
Lamotrigine Level
Topiramate Level
Levetiracetam Level
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CASE PRESENTATION

• Valproate is an anticonvulsant widely used to
treat seizures. Its use has been linked to
Hyperammonemic Encephalopathy (HE), a rare
complication.
• VHE is characterized by decreased levels of
consciousness, focal neurologic deficits,
cognitive slowing, drowsiness and lethargy.
• The pathophysiology behind these manifestations
is not entirely understood.
• These findings may even occur with normal
therapeutic drug levels.
• VHE is more common in patients who employ
polytherapy with anticonvulsants such as
phenobarbital or topiramate.

CT BRAIN: STABLE LEFT FRONTAL ENCEPHALOMALACIA.
NO ACUTE PROCESS.
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AMMONIA LEVEL
7/19/19
108
7/22/19
67
7/23/19
66
7/26/19
23
7/27/19
66
7/28/19
90
7/29/19
64
7/30/19
63
7/31/19
83
8/1/19
43
LEVEL
91
9.0
9.1
22.2

•

DISCUSSION

We present a case of a 29-year-old African
American male with intractable epilepsy
secondary to traumatic brain injury and a
remote history of a left frontal CVA with
associated right hemiparesis. He was initially
admitted to the hospital with complaints of
headache, confusion, weakness and multiple
seizures. He continued to experience seizures in
acute care despite treatment with 5 different
antiepileptic medications, including
Lamotrigine, Levetiracetam, Lacosamide,
Clobazam, and Valproic Acid.

• This patient was at increased risk for developing
VHE due to receiving treatment with several
antiepileptics, despite therapeutic levels of
Valproic Acid.

On admission, his ammonia levels were found to
be elevated and peaked at 108. Valproic acid
was discontinued and he was started on
Lactulose, Rifaximin, and Clobazam. The
patient’s ammonia levels improved to 43 at the
time of admission to the inpatient rehabilitation
facility (IRF), and he remained seizure-free for
two days. His initial course in rehabilitation was
complicated by recurrent seizures leading to a
short return to acute care. However, upon
readmission to IRF, he continued to have
intermittent seizures leading to ongoing
neurologic insult hindering his progress.

• Management focuses on reducing ammonia
levels with Lactulose and Rifaximin, as well as
stopping the offending agent. Some studies also
suggest carnitine supplementation, as valproic
acid can lead to carnitine deficiency.

The patient’s seizures eventually subsided, and
significant progress was made with extensive
rehabilitation. Comprehensive physical,
occupational, and speech therapies lead to
meaningful improvement in FIM scores (51 to
87).
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• Diagnosis of VHE is supported by elevated
ammonia levels and EEG findings consistent with
severe encephalopathy. EEG typically
demonstrate continuous generalized slowing, a
predominance of theta and delta activity,
occasional bursts of frontal intermittent rhythmic
delta activity, and triphasic waves.

CONCLUSION
• This case demonstrates the unique challenges of
a patient with intractable epilepsy with a
complex and carefully balanced medication
regimen complicated by continued neurologic
insult during his rehabilitation course.
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